In-Depth Research On:
Epizyme, Inc. (EPZM)

Sign Up Now to Download a Free Research Report on EPZM

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts

Select your areas of interest / would you like to receive the newsletter?




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Epizyme, Inc.

Epizyme shares jumped $4.36 to close at $338.97 a share Thursday. The stock traded between $34.79 and $40.98 on volume of 1.22 million shares traded. The company has announced plans to initiate Phase 2 POC clinical studies of EPZ-5676 in MLL-r pediatric patients and EPZ-6438 in non-Hodgkin lymphoma patients in the fourth quarter of 2014. Shares of Epizyme are up approximately 76.0 percent year-to-date.

Going forward ... (see research report)


RESEARCH REPORT ON EPZM
Download Free Report Now


Preview Pages of Actual Research Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on